The invention also discloses application of ErbB3 protein in preparation of bladder urothelium carcinoma non-invasive diagnosis product

Abstract

The invention discloses application of ErbB3 protein in preparation of a bladder urothelium carcinoma non-invasive diagnosis product. The method comprises the following steps of medical history query,preparation before diagnosis, diagnosis material preparation, formal detection, detection result analysis and final conclusion obtainment. The structure is reasonable, use is safe and convenient; andwhether a patient suffers from the bladder urothelium carcinoma or not can be diagnosed by detecting the content of ErbB3 protein in urine of the patient. The ErbB3 protein is used for distinguishingdiagnosis boundary values of bladder high-grade urothelial carcinoma and low-grade urothelial carcinoma, tumor malignant-grade information can be provided by detecting the ErbB3 content in urine of the patient; and a certain reference value is provided for preoperative evaluation and postoperative follow-up visit. Besides, the muscular layer infiltration type bladder urothelium carcinoma is proneto distant metastasis, and the non-invasive diagnosis product is used for diagnosing the boundary value of the ErbB3 protein in the urine of the patient to the muscular layer infiltration type tumor;and the application of ErbB3 protein has very important significance for more accurate clinical diagnosis and making of a treatment strategy.

Description

Technical field [0001] The invention relates to the technical field of diagnosis of bladder cancer, in particular to the application of ErbB3 protein in the preparation of non-invasive diagnosis products for bladder urothelial cancer. Background technique [0002] Bladder cancer refers to a type of malignant tumor that occurs in the bladder. Most of its tissue types are urothelial cancers. According to the morphology and biological behavior of tumor cells, it can be divided into high-grade urothelial cancer and low-grade urothelial cancer. According to the degree of invasion, it can be divided into invasive urothelial carcinoma and non-invasive urothelial carcinoma. At present, the incidence of bladder urothelial carcinoma is on the rise, and it is the first tumor in the urogenital system. Therefore, Improving the diagnosis and treatment of bladder tumors is of great significance to national health; [0003] The clinical manifestations of patients with bladder cancer are mostly pa...

AI Technical Summary

Problems solved by technology

[0004] The present invention provides the application of ErbB3 protein in the preparation of non-invasive diagnosis products for bladder cancer, which can effectively solve the problem of taking specimens for pathological biopsy through urethral cystoscopy proposed in the background technology, which is currently the gold standard for diagnosing bladder tumors, but this method is invasive. , and it is not easy to promote population screening. Urine exfoliation cytology is also a commonly used method, but this method has low sensitivity and is easily affected by urinary tract infection and stones.

Images